Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Biosimilar SB2 May Work as Well as Infliximab for Rheumatoid Arthritis

  |  

Overall, the results reinforce the recent observations in the NOR-SWITCH and DANBIO studies. The authors conclude that the long-term clinical profile of SB2 is comparable with infliximab.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: Results of a randomised, double-blind, Phase III transition study. Ann Rheum Dis. 2017 Oct 17. pii: annrheumdis-2017-211741. doi: 10.1136/annrheumdis-2017-211741. [Epub ahead of print]

Related Articles

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Medicalwriters/Science Source

    Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

    As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

    Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

    SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

    Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

    AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at…